Dramatic improvement in 1-year survival for patients with acute promyelocytic leukemia

Clinical trials have reported rates of >95% durable remissions, but population studies from national registries report 1-year survival far below, namely at 70% and 5-year survival between 55 to 70%.

In this MEDtalk Anand P. Jillella, MD, from the Georgia Cancer Center at Augusta University, USA, explains how he and his colleagues succeeded with these dramatic improvements in 1-year survival for this group of patients.